| BMY |
Report |
Non-GAAP EPS |
BEAT |
pred ~$1.75 vs. cons ~$1.60 |
HIGH |
| BMY |
Report |
Total revenue |
BEAT |
pred ~$11.95B vs. cons ~$11.70B |
MEDIUM |
| BMY |
Report |
Cobenfy revenue |
MISS |
pred ~$62M vs. cons ~$78M |
MEDIUM |
| BMY |
Guide |
FY26 revenue guide |
BETTER |
guide ~$47.5B (raised to upper end) vs. cons ~$46.9B (FY2026) |
MEDIUM |
| BMY |
Guide |
FY26 non-GAAP EPS guide |
BETTER |
guide ~$6.35 (raised to top end) vs. cons ~$6.25 (FY2026) |
MEDIUM |
| BMY |
Guide |
Eliquis Q2 sales (inventory reversal read-through) |
LOWER |
guide ~$3.0B vs. cons ~$3.2B (Q2 2026, sequential reversal of Q1 price-cut build) |
LOW |
| BMY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| BMY |
Return |
5-day cumulative residual |
-3.0% (FADE) |
Stock ran ~17% in a month to a fresh 52-week high (~$63.67), so a beat-and-raise is largely priced and sets up 'sell-the-news' risk. The likely beat is low-quality (legacy Eliquis inventory timing, tough Revlimid comps rolling off), and the out-period patent-cliff math pulls 2027+ estimates down even after a headline beat/raise. Any softness in Cobenfy ramp or Opdivo inventory normalization gives profit-takers a reason after the strong YTD run, driving negative revisions and a fade. |
MEDIUM |